Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $809,000 in Adaptive Biotechnologies Corporation $ADPT
05:16am, Monday, 05'th Jan 2026
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) in the third quarter, according to its most recent disclosure with the Securiti
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 30'th Dec 2025
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
08:24am, Monday, 15'th Dec 2025
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
08:00am, Monday, 15'th Dec 2025
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
05:07pm, Tuesday, 09'th Dec 2025
SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
01:33pm, Friday, 05'th Dec 2025
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostic
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation $ADPT Stock Position Reduced by Campbell & CO Investment Adviser LLC
04:38am, Monday, 17'th Nov 2025
Campbell and CO Investment Adviser LLC trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 76.7% in the second quarter, according to its most recent 13F filing with the Secu
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 06'th Nov 2025
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript
07:56am, Thursday, 06'th Nov 2025
Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder,
Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say
08:31pm, Wednesday, 05'th Nov 2025
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
07:36pm, Wednesday, 05'th Nov 2025
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago.
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Wednesday, 29'th Oct 2025
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
